Kuros Biosciences AG Stock Swiss Exchange
Equities
CH0325814116
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.585 CHF | +216.04% | +0.42% | +3.91% |
Apr. 17 | Kuros Biosciences AG Approves Board of Director and Committee Changes | CI |
Mar. 13 | Kuros Biosciences' FY23 Attributable Loss Shrinks; Revenue Up | MT |
Sales 2022 | 17.99M 19.72M | Sales 2023 | 33.56M 36.8M | Capitalization | 128M 141M |
---|---|---|---|---|---|
Net income 2022 | -14M -15.35M | Net income 2023 | -13M -14.25M | EV / Sales 2022 | 1.76 x |
Net cash position 2022 | 22.08M 24.21M | Net cash position 2023 | 12M 13.15M | EV / Sales 2023 | 3.46 x |
P/E ratio 2022 |
-3.41
x | P/E ratio 2023 |
-9.18
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.71% |
Managers | Title | Age | Since |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 23-02-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott P. Bruder
BRD | Director/Board Member | 62 | 18-06-13 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
1st Jan change | Capi. | |
---|---|---|
+2.49% | 96.73B | |
-0.52% | 21.31B | |
-16.61% | 21.21B | |
-5.34% | 18.79B | |
-42.14% | 16.37B | |
-27.40% | 13.68B | |
+1.44% | 13.44B | |
+21.29% | 10.98B | |
-21.79% | 8.56B |